Overview

Exploratory Study to Evaluate Various Pharmacodynamic Effects of Subcutaneously Infused or Injected Pramlintide in Obese Subjects

Status:
Completed

Trial end date:
2005-05-01

Target enrollment:

Participant gender:

Summary

This exploratory study is designed to evaluate various pharmacodynamic effects of subcutaneously (SC) infused or injected pramlintide in obese, nondiabetic male and postmenopausal female (not on hormone replacement therapy) subjects. The study will also assess the safety and tolerability of pramlintide administered by SC infusion or injection.

Phase:

Phase 2

Details

Lead Sponsor:

AstraZeneca

Treatments:

Islet Amyloid Polypeptide
Pramlintide